Evidence map›Paper›PMID 39430748›Full record

ArticleFrontiers in immunology2024

Development of a risk prediction model for the first occurrence of thrombosis in patients with OAPS.

Jie Gao, Yan Zheng, Zhuo Wang, Junfeng Jia, Jian Wan, Qing Han, Xi Zheng, Renli Liu, Zhaohui Zheng, Kaichun Wu and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jie Gao *Department of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Yan Zheng *Department of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Zhuo Wang *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, China.
Junfeng Jia *Department of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Jian Wan *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, China.
Qing HanDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Xi ZhengDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Renli LiuDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Zhaohui ZhengDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Kaichun WuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, China.
Ping ZhuDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The aim of this study is to assess the risk factors associated with thrombotic events in obstetric antiphospholipid syndrome (OAPS) patients and to develop a predictive model specifically tailored to predict the risk of postpartum thrombosis in OAPS patients without prior thrombotic events. This research seeks to enhance clinician's awareness regarding the postpartum care and monitoring of OAPS patients. Methods: A retrospective study was conducted at the First Affiliated Hospital of the Fourth Military Medical University including 269 consecutive inpatients diagnosed with antiphospholipid syndrome (APS) from July 1, 2008 to July 31, 2022. All participants met the 2006 Sydney APS classification criteria or the "non-criteria OAPS classification". Out of 98 candidate clinical and laboratory parameters considered, 40 potential variables were selected for analysis based on expert opinion. The logistic regression mode with the Least Absolute Shrinkage and Selection Operator (LASSO) were used to identify optimal predictive characteristics. All samples were included in the model building and a nomogram was generated based on these characteristics. The differentiation, calibration, and clinical utility of the predictive model were evaluated using the area under the curve (AUC), calibration curve, and decision curve analysis. The model was also validated by a 1000 bootstrap tests. Results: 126 patients with OAPS were enrolled, and a total of 89 OAPS patients who had never experienced thrombosis were retrospectively analyzed. After 3 years follow-up, 32.58% of the patients (29/89) developed thrombosis. In order to create, LASSO logistic regression identified three optimal variables: the platelet count less than 125×109/L, more than one positive aPLs (antiphospholipid antibody), and the use of low molecular weight heparin (LMWH) or low dose aspirin (LDA) after delivery. A predictive model was conducted using these three predictive indicators for patients with OAPS who experience thrombosis for the first-time. This prediction model has good distinction, good calibration, and fair clinical practicality. Conclusion: Our model has good predictive ability in assessing the risk of thrombosis in patients with OAPS without prior thrombotic events. This model is easy to predict, has good discriminability and calibration, and can be utilized as a routine tool for thrombus screening in OAPS patients.

Indexed as

Antiphospholipid SyndromeThrombosisAdultFemaleHumansNomogramsPregnancyRetrospective StudiesRisk AssessmentRisk Factorsantiphospholipid antibodiesantiphospholipid syndromenomogramobstetric antiphospholipid syndromethrombosis

Identifiers

PMID39430748
PMCPMC11486719

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.